Calumet (CLMT) Q2 2026 earnings review
Specialties Outperformance Masks RIN-Driven Net Loss
Calumet delivered a robust top-line acceleration in Q2 2026, with revenue surging 41% YoY to $1.44 billion. The growth was heavily concentrated in the Specialty Products and Solutions (SPS) segment, which capitalized on a global shortage in specialty products to drive Adjusted EBITDA up 189% YoY to $161.7M. Despite this operational cash strength, the bottom line remained printed in red with a Net Loss of $(95.9)M, heavily penalized by a staggering $163.6M non-cash RINs expense. Encouragingly, the underlying cash engine allowed the company to retire $115M in debt shortly after the quarter closed and successfully complete the first phase of its MaxSAF 150 expansion.
🐂 Bull Case
The Specialty Products segment is capturing massive margins due to global supply shortages and strong commercial execution, generating enough cash to fund the entire business and debt reduction.
Management continues to execute its balance sheet repair, redeeming $100M of 2028 notes and retiring a $15.5M terminal financing facility in July alone.
🐻 Bear Case
The $163.6M non-cash RINs expense completely wiped out operational gains on the GAAP income statement, highlighting severe vulnerability to regulatory compliance costs.
Despite record TruFuel volumes, the PB segment saw EBITDA cut in half due to the lag in passing escalating feedstock costs to retail consumers.
⚖️ Verdict: ⚪
Neutral to Bullish. The GAAP net loss looks ugly on the surface, but the underlying cash generation is exceptionally strong. As long as SPS margins hold up and Montana Renewables ramps smoothly, Calumet is generating the cash it needs to de-risk its balance sheet.
Key Themes
SPS Segment Strength Accelerates
The SPS segment reported Adjusted EBITDA of $161.7M, an accelerating 142% YoY increase compared to $66.8M a year ago. Management attributed this to a structural global shortage in specialty products, allowing Calumet to demonstrate exceptional commercial execution, push through price increases, and maintain robust production. This segment is single-handedly funding the company's deleveraging goals.
Performance Brands Margin Compression
In stark contrast to SPS, the Performance Brands segment decelerated sharply. Adjusted EBITDA fell 53% YoY from $13.5M to $6.3M. While TruFuel hit record volumes, the segment suffered from a structural price-increase lag amidst rapidly escalating feedstock costs, resulting in compressed margins and a $7.3M LIFO inventory hit.
MaxSAF 150 Phase 1 Completion
Montana Renewables completed its planned turnaround and the first phase of the MaxSAF 150 expansion. Operations restarted in May into what management described as a 'robust renewable margins' environment, driving MRL Adjusted EBITDA with Tax Attributes to $26.6M (up 63% YoY) and turning standard segment Adjusted EBITDA positive ($10.7M vs a loss of $5.1M a year ago).
Accelerated Debt Reduction Execution
Calumet utilized its strong Q2 cash flow to accelerate deleveraging immediately after quarter-end. On July 15, the company redeemed all $100M of its 9.75% 2028 Senior Notes. Two weeks later, it fully repaid a $15.5M Montana terminal asset financing arrangement.
Escalating RINs Obligations
The company absorbed a staggering $163.6M non-cash RINs expense in Q2, up significantly from prior periods. This massive charge was the primary driver pulling the company into a $95.9M GAAP net loss, underscoring the ongoing volatility and drag that regulatory compliance places on statutory earnings.
Other KPIs
Accelerating significantly from $76.5M in Q2 2025. This metric best reflects the core cash-generating power of the business by adding back the notional value of generated Clean Fuel Production Credits (CFPCs) and stripping out the non-cash RINs mark-to-market chaos.
A massive acceleration from $13.81 in the prior year period. This highlights the intense pricing power Calumet currently wields in the specialty products market due to global supply shortages.
Reversing from a cash burn of $(31.1)M in the first half of 2025. Improved operational margins and strategic cost discipline have restored positive cash generation despite severe working capital headwinds.
Key Questions
RINs Mitigation Strategy
With the $163.6M non-cash RINs expense wiping out GAAP profitability this quarter, what structural or hedging mechanisms are being evaluated to minimize this specific exposure going forward?
Performance Brands Margin Recovery
Given the 60-90 day pricing lag in Performance Brands, should we expect margins to fully normalize in Q3, or are there lingering LIFO/feedstock impacts to model in?
MaxSAF Stage 2 Timeline
You noted advancing toward a 'faster, highly capital-efficient next stage expansion' for MaxSAF. Can you quantify the expected capital requirements and target operational date for this next phase?